Therapeutic Asset Ratings

435 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Vorinostat Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	OHSU Knight Cancer Institute	P1/2	B (57)
PENTOSTATIN Acute Myeloid Leukemia	OHSU Knight Cancer Institute	P3	B (56)
Vorinostat Plasma Cell Myeloma	OHSU Knight Cancer Institute	P3	B (56)
Abemaciclib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (55)
Arimidex Ovarian Cancer	OHSU Knight Cancer Institute	P2	CCC (55)
Cobimetinib Breast Cancer	OHSU Knight Cancer Institute	P2	CCC (55)
Eloxatin Chronic Myelomonocytic Leukemia	OHSU Knight Cancer Institute	P2	CCC (55)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	CCC (55)
Ipilimumab Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (55)
Olaparib Pancreatic Ductal Adenocarcinoma	OHSU Knight Cancer Institute	P2	CCC (55)
Oxodotreotide Advanced Breast Cancer	OHSU Knight Cancer Institute	P2	CCC (55)
su011248 Lymphoma, Non-Hodgkin	OHSU Knight Cancer Institute	P2	CCC (55)
TRASTUZUMAB Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	CCC (55)
Vinorelbine Chronic Myelomonocytic Leukemia	OHSU Knight Cancer Institute	P2	CCC (55)
Carboplatin Soft Tissue Sarcoma	OHSU Knight Cancer Institute	P1/2	CCC (55)
Cobimetinib Breast Carcinoma	OHSU Knight Cancer Institute	P1/2	CCC (55)
gsk1120212 Metastatic Malignant Neoplasm	OHSU Knight Cancer Institute	P1/2	CCC (55)
Alpelisib Ovarian Cancer	OHSU Knight Cancer Institute	P3	CCC (54)
Cobimetinib Non-Hodgkin Lymphoma	OHSU Knight Cancer Institute	P2	CCC (54)
TANCIN Pancreatic Adenocarcinoma	OHSU Knight Cancer Institute	P2	CCC (54)
TANCIN Malignant Pancreatic Neoplasm	OHSU Knight Cancer Institute	P2	CCC (54)
Atezolizumab Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	P1/2	CCC (54)
Atezolizumab Soft Tissue Sarcoma	OHSU Knight Cancer Institute	P1/2	CCC (54)
Durvalumab Hematopoietic And Lymphoid System Neoplasm	OHSU Knight Cancer Institute	P1/2	CCC (54)
Everolimus Acute Lymphoblastic Leukemia	OHSU Knight Cancer Institute	P1/2	CCC (54)

Showing 201 to 225 of 435 assets

PreviousPage 9 of 18Next